| | 
| | |  |  | Webcast
Idera Pharmaceuticals, Inc. at Rodman & Renshaw Global Investment Conference (Live)
09/15/10 at 10:50 a.m. ET |
| Webcast
Idera Pharmaceuticals, Inc. at UBS Global Life Sciences Conference (Live)
09/20/10 at 7:30 a.m. ET |
|
|
|
| Date | Title | | | 12/22/08 | Massachusetts General Hospital and Idera Pharmaceuticals Receive Cooperative Research Grant from Massachusetts Life Sciences Center for Developing New Therapies for Lupus| BOSTON & CAMBRIDGE, Mass., Dec 22, 2008 (BUSINESS WIRE) -- Dr. Andrew Luster, Chief of the Division of Rheumatology, Allergy, and
Immunology at Massachusetts General Hospital (MGH), and Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA), a drug discovery and development
company focused on therapeutics targeting Toll-like Receptors (TLR),
have received a Cooperative Research Grant from the Massachusetts Life
Sciences Center (MLSC). Under the collaboration between D... |
|  | | 12/08/08 | Idera Pharmaceuticals to Present at 10th Annual Massachusetts Biotechnology Investors Forum| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 8, 2008--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a drug discovery and
development company focused on therapeutics targeting Toll-like
Receptors (TLR), today announced that it will discuss its TLR-targeted
drug discovery and development programs and provide a general corporate
overview at the 10th Annual Massachusetts Biotechnology Investors Forum
on Tuesday, December 9 at 4:20 p.m. (ET) at the Sheraton Hotel in Bo... |
| | | 11/20/08 | Idera Pharmaceuticals and Merck & Co., Inc. Extend Research Collaboration for Agonists of Toll-like Receptors| CAMBRIDGE, Mass., Nov 20, 2008 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that Merck &
Co., Inc. has extended its research collaboration with Idera for an
additional year. The Company and Merck entered into an exclusive license
and research collaboration agreement to research, develop and
commercialize vaccine products containing the Company's investigational
agonist compounds targeting Toll-like Receptors (TLR) 7, 8, and... |
| | | 11/06/08 | Idera Pharmaceuticals Reports Third Quarter 2008 Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 6, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported financial results
for the third quarter and nine months ended September 30, 2008.
"We are pleased that our business strategy is allowing us to
advance multiple therapeutic applications of our TLR-targeted drug
candidates, through three collaborations and a diverse internal
pipeline, with a disciplined use of financial resources," said Sudhir
Agrawal, D.Phil., Chief Executive ... |
| | | 10/27/08 | Idera Pharmaceuticals to Present at Upcoming Investor Conferences| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 27, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA), a drug discovery and development
company focused on therapeutics targeting Toll-like Receptors (TLR),
today announced that it will discuss its TLR-targeted drug discovery
and development programs and provide a general corporate overview at
the following conferences:
BIO Investor Forum 2008, on Thursday, October 30 at 2:15 p.m.
PT (5:15 p.m. ET) at the Palace Hotel in San Francisco... |
| | | 10/16/08 | Idera Pharmaceuticals Presents Data from Autoimmune Disease Program at 4th Annual Meeting of the Oligonucleotide Therapeutics Society| CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it
will present preclinical data from studies on its autoimmune disease
program at the 4th Annual Meeting of the Oligonucleotide Therapeutics
Society being held at the Harvard Medical School Conference Center in
Boston, October 15-18, 2008. The Company's presentations describe
studies of novel compounds targeted to Toll-like Receptors (TLRs),
including the evaluation of TLR antagonist... |
| | | 10/06/08 | Idera Pharmaceuticals Announces Issuance of Patents for Novel Immune Modulatory Oligonucleotides Targeting Toll-Like Receptors and their Use| CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the
issuance of patents covering its novel immune modulatory
oligonucleotides (IMO), chemical modifications of IMOs, and methods of
inducing an immune response through administering such compounds.
The issued patents include:
US 7,427,405, entitled "Immunostimulatory Oligonucleotide
Multimers"
US 7,407,944, entitled "Modulation of Immunostimulatory
P... |
| | | 10/01/08 | Idera Pharmaceuticals Announces Preliminary Data from Phase 2a Clinical Study of IMO-2055 Monotherapy in Renal Cell Carcinoma| CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced
preliminary data from the first part of a Phase 2 clinical study
conducted by the Company of IMO-2055 monotherapy in patients with
metastatic or recurrent clear cell renal carcinoma (RCC). The primary
objective was not achieved in the study. The primary objective was
tumor response based on RECIST (Response Evaluation Criteria In Solid
Tumors). Secondary objectives included time to progress... |
| | | 09/30/08 | Idera Pharmaceuticals to Present at JMP Securities Healthcare Focus Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biopharmaceutical
company focused on developing therapeutics targeting Toll-Like
Receptors (TLR), today announced that it will discuss its TLR-targeted
drug discovery and development programs and provide a general
corporate overview at The Third Annual JMP Securities Healthcare Focus
Conference on Monday, October 6, 2008 at 9:00 a.m. (ET) at Le Parker
Meridien Hotel in New York City.
The presentatio... |
| | | 09/17/08 | Idera Pharmaceuticals to Present at UBS Global Life Sciences Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 17, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA), a biopharmaceutical company
focused on developing therapeutics targeting Toll-Like Receptors
(TLR), today announced that it will discuss its TLR-targeted drug
discovery and development programs and provide a general corporate
overview at the UBS Global Life Sciences Conference on Monday,
September 22, 2008 at 9:00 a.m. (EDT) at the Grand Hyatt New York
Hotel in New York City.
The presen... |
| | | 09/02/08 | Idera Pharmaceuticals Announces Milestone Payment Under Asthma and Allergy Collaboration| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 2, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will
receive a milestone payment from Novartis under the two companies'
research collaboration and license agreements. Under the terms of the
agreement, the payment was triggered by the initiation of a Phase 1
clinical study by Novartis of QAX935. QAX935 is a novel agonist of
Toll-Like Receptor 9 (TLR9) exclusively licensed by Idera to Novartis.
"We are pleased tha... |
| | | 08/04/08 | Idera Pharmaceuticals Reports Second Quarter 2008 Financial Results| IMO-3100 Selected as Lead Toll-Like Receptor Antagonist Candidate
in Autoimmune Disease Indications
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 4, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA), a biopharmaceutical company
focused on developing therapeutics targeting Toll-Like Receptors
(TLR), today reported financial results for the second quarter and six
months ended June 30, 2008.
"We continue to build on our chemistry-based drug discovery
platform for designing TLR-targ... |
| | | 07/30/08 | Idera Pharmaceuticals to Present at Upcoming Investor Conferences| CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 30, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA), a biopharmaceutical company
focused on developing therapeutics targeting Toll-Like Receptors
(TLR), today announced that it will discuss its TLR-targeted drug
discovery and development programs and provide a general corporate
overview at the following conferences:
BMO Capital Markets Focus on Healthcare Conference, on
Wednesday, August 6, 2008 at 10:45 a.m. (EDT) at the
Mi... |
| | | 06/16/08 | Idera Pharmaceuticals Forms Autoimmune Disease Scientific Advisory Board| CAMBRIDGE, Mass., Jun 16, 2008 (BUSINESS WIRE) -- Idera Pharmaceuticals (Nasdaq: IDRA), a biopharmaceutical company
focused on developing therapeutics targeting Toll-Like Receptors
(TLRs), today announced the formation of an Autoimmune Disease
Scientific Advisory Board.
"We are pleased to have the participation of distinguished
clinicians and researchers with extensive experience in the field of
autoimmune diseases and biomarkers," said Sudhir Agrawal, D. Phil.,
Chief Executive Officer a... |
| | | 06/13/08 | Idera Pharmaceuticals to Present at BIO Business Forum 2008| CAMBRIDGE, Mass., Jun 13, 2008 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biopharmaceutical
company focused on developing therapeutics targeting Toll-Like
Receptors (TLR), today announced that it will present at the 2008 BIO
International Convention taking place June 17-20, 2008 in San Diego,
CA. The Company will discuss its TLR-targeted drug discovery and
development programs and provide a general corporate update. The
presentation will be delivered on Wednesday, Jun... |
| | | 06/09/08 | Idera Pharmaceuticals Presents Preclinical Data of Toll-Like Receptor Antagonists in Models of Lung Inflammation and Psoriasis| CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 9, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that
presentations from studies evaluating its novel Toll-like Receptor
(TLR) antagonist candidates in preclinical models of lung inflammation
and psoriasis were made at the Federation of Clinical Immunology
Societies (FOCIS) 2008 Annual Meeting held in Boston, MA, June 5-9.
Study # OR.53 "Prevention and Treatment of Ovalbumin-induced
Inflammation in Mice with Toll-lik... |
| | | 05/12/08 | Idera Pharmaceuticals Reports First Quarter 2008 Financial Results| CAMBRIDGE, Mass., May 12, 2008 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biopharmaceutical
company focused on developing therapeutics targeting Toll-Like
Receptors (TLR), today reported financial results for the quarter
ended March 31, 2008.
"Development of our novel agonist candidates of TLR9 is ongoing in
multiple applications including hepatitis C, asthma and allergies,
cancer, and for use as vaccine adjuvants through proprietary programs
and partnered programs,... |
| | | 05/01/08 | Idera Pharmaceuticals Achieves Preclinical Milestone Under Collaboration with Merck & Co., Inc.| CAMBRIDGE, Mass., May 01, 2008 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that, under its collaboration agreement with Merck & Co., Inc., a
preclinical milestone was achieved with one of its novel Toll-Like
Receptor (TLR) 9 agonists used as an adjuvant in cancer vaccines. As a
result, Idera is eligible to receive a milestone payment from Merck.
Under the terms of the agreement, Idera and Merck are
collaborating to research, develop and commercialize Ide... |
| | | 04/17/08 | Idera Pharmaceuticals Presents Data from Study of Toll-Like Receptor Antagonist in Preclinical Model of Multiple Sclerosis| CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 17, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced the presentation
of data from studies evaluating a Toll-Like Receptor (TLR) antagonist
in a preclinical model of multiple sclerosis (MS). The presentation
entitled "Studies of Oligonucleotide-Based Antagonists of TLR9 in a
Mouse Model of Experimental Autoimmune Encephalomyelitis" (Abstract
#2049) was made during the 60th Annual Meeting of the American Academy
of Neurology bei... |
| | | 04/09/08 | Idera Pharmaceuticals to Present Preclinical Data of its Toll-Like Receptor - Targeted Compounds at AACR Meeting| CAMBRIDGE, Mass., Apr 09, 2008 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that preclinical data from its Toll-Like Receptor (TLR) programs will be
presented at the 2008 Annual Meeting of the American Association for
Cancer Research (AACR) being held in San Diego, CA, April 12-16, 2008.
Monday, April 14, 8:00AM-12:00PM (PDT): Immune Modulation 1
Session
Abstract 2094 entitled "Preclinical antitumor studies of RNA-based
agonists of TLR7 and 8" will be pr... |
| | | 04/08/08 | Idera Pharmaceuticals Announces Issuance of Patents Claiming Novel Immune Modulatory Oligonucleotides Targeting Toll-Like Receptors| CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 8, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of
several patents. The claims of these patents cover novel immune
modulatory oligonucleotides (IMO) and chemical modifications of IMOs,
each of which provide unique immune responses.
The issued patents include:
US 7,354,907, entitled "Short Immunomodulatory
Oligonucleotides"
US 7,329,648, entitled "Modulation of Oligonucleotide
... |
| | | 03/13/08 | Idera Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 13, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA), a biopharmaceutical company
focused on developing therapeutics targeting Toll-Like Receptors
(TLR), today announced that it will present at the Cowen and Company
28th Annual Health Care Conference. The Company will discuss its
TLR-targeted drug discovery and development programs and provide a
general corporate update. The presentation will be delivered on
Thursday, March 20, 2008 at 10:15 a.... |
| | | 03/04/08 | Idera Pharmaceuticals Reports Financial Results for Fourth Quarter and Full Year Ended December 31, 2007| CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 4, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported financial results
for the fourth quarter and full year ended December 31, 2007.
"During 2007 we made substantial progress in advancing our drug
candidate pipeline and expanding the potential applications of our
TLR-targeted compounds. We initiated a phase 1 clinical trial of our
lead candidate for infectious diseases, IMO-2125, in patients with
chronic hepatitis C virus infe... |
| | | 02/28/08 | Idera Pharmaceuticals to Participate in Discussion Panel at SIGnificant Investment Options in Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 28, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that Sudhir
Agrawal, D. Phil., Chief Executive Officer and Chief Scientific
Officer, will participate in a biotechnology discussion panel during
the Second Annual SIGnificant Investment Options in Healthcare
Conference taking place at The W Hotel in New York City March 4-5,
2008.
The biotechnology discussion panel entitled, "Lupus: Crossing the
Finish Line, New Therapies f... |
| | | 02/08/08 | Idera Pharmaceuticals to Participate in Therapeutic Workshop at BIO CEO & Investor Conference 2008| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 8, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that Sudhir
Agrawal, D. Phil., Chief Executive Officer and Chief Scientific
Officer, will participate in a therapeutic workshop during the 10th
Annual BIO CEO & Investor Conference 2008 taking place at the
Waldorf=Astoria hotel in New York City February 11-13, 2008.
The therapeutic workshop, entitled, "Non-Cancer Immunotherapy:
It's not just about cancer anymore" will begin ... |
| | | 02/06/08 | Idera Pharmaceuticals Announces Hart-Scott-Rodino Clearance for Collaboration Agreement with Merck KGaA| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA) announced today that it received
clearance under the Hart-Scott-Rodino Antitrust Improvements Act for
its worldwide licensing and collaboration agreement with Merck KGaA of
Darmstadt, Germany, announced in December 2007. With the grant of HSR
clearance, the agreement is now in effect and Idera is entitled to
receive an upfront licensing fee of $40 million from Merck KGaA.
Under the agreemen... |
| | | 01/24/08 | Idera Pharmaceuticals to Present at Wachovia 2008 Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 24, 2008--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA), a biopharmaceutical company
focused on developing therapeutics targeting Toll-Like Receptors
(TLR), today announced that it will present at the Wachovia 2008
Healthcare Conference. The Company will discuss its TLR-targeted drug
discovery and development programs and provide a general corporate
update. The presentation will be delivered on Wednesday, January 30,
2008 at 1:30 p.m. (EST) at the ... |
| | | 01/10/08 | Idera Pharmaceuticals Announces Management Promotions| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2008--Idera
Pharmaceuticals (Nasdaq: IDRA) today announced the promotion of Steven
J. Ritter, Ph.D., J.D., to Vice President of Intellectual Property and
Contracts, and the promotion of Ekambar R. Kandimalla, Ph.D., to Vice
President of Discovery.
"Over the last two years Steve has played a pivotal role in
advancing Idera's intellectual property initiatives and building a
portfolio to include more than 500 issued and pending patent
appl... |
| |
|
|
| |
